

**LUMI-CELL[®] ER ASSAY
AGONIST PROTOCOL**

**National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative
Toxicological Methods (NICEATM)**

**Developed by:
Xenobiotic Detection Systems, Inc.
1601 E. Geer St., Suite S
Durham, NC 27704**

TABLE OF CONTENTS

1

2 **List of Abbreviations and Acronymsiii**

3 **1.0 Purpose 1**

4 **2.0 Definitions..... 1**

5 **3.0 Controls and Reference Standards 1**

6 **4.0 Overview of General Procedures for Agonist Testing 2**

7 4.1 Range Finder Testing..... 4

8 4.2 Comprehensive Testing..... 4

9 **5.0 Materials for LUMI-CELL® ER Assay Agonist Testing 4**

10 5.1 BG1Luc4E2 Cells..... 4

11 5.2 Equipment and Supplies..... 5

12 **6.0 Preparation of Tissue Culture Media and Solutions..... 6**

13 6.1 RPMI 1640 Growth Medium (RPMI)..... 6

14 6.2 Estrogen-free DMEM Medium 6

15 6.3 1X Trypsin Solution..... 7

16 6.4 1X Lysis Solution 7

17 6.5 Reconstituted Luciferase Reagent 8

18 **7.0 Overview of Propagation and Experimental Plating of BG1Luc4E2 Cells..... 8**

19 7.1 Conditioning in Estrogen-free Medium, and Plating Cells for

20 Experimentation..... 8

21 **8.0 Preparation of Test Substances..... 9**

22 8.1 Preparation of Reference Standards, Control and Test Substances for

23 Range Finder and Comprehensive Testing 9

24 8.1.1 Preparation of Reference Standard Control Stock

25 Solutions 9

26 8.1.2 Preparation of Reference Standard, Control, and Test

27 Substance Dosing Solutions for Range Finder Testing..... 9

28 8.1.3 Preparation of Reference Standard and Control Dosing

29 Solutions for Comprehensive Testing 9

30 8.1.4 Preparation of Test Substance Dosing Solutions for

31 Comprehensive Testing 10

32	9.0	Data Analysis	10
33	9.1	Adjusting and Normalizing RLU Values	10
34	9.1.1	Determination of Outliers	11
35	9.1.2	Acceptance Criteria	11
36	10.0	Range Finder Testing	11
37	11.0	Comprehensive Testing	12
38			
39			
40			

40 LIST OF ACRONYMS AND ABBREVIATIONS		
41	13 mm test tube	13 x 100 mm glass test tubes
42	DMEM	Dulbecco's Modification of Eagle's Medium
43	DMSO	Dimethyl Sulfoxide
44	DMSO control	1% v/v dilution of DMSO in tissue culture media used as a
45		vehicle control
46	E2	17 β -estradiol
47	E2 reference standard	10 Point Serial Dilution of 17 β -estradiol reference standard
48		for the LUMI-CELL [®] ER agonist assay
49	EC ₅₀ value	Concentration that produces a half-maximal response as
50		calculated using the four parameter Hill function.
51	ER	Estrogen Receptor
52	Estrogen-free DMEM	DMEM (phenol red free) supplemented with 1%
53		Penicillin/Streptomycin, 2% L-Glutamine, and 5%
54		Charcoal-dextran treated FBS
55	FBS	Fetal Bovine Serum
56	G418	Gentamycin
57	Methoxychlor	<i>p,p'</i> -Methoxychlor
58	Methoxychlor control	3.13 μ g/mL Methoxychlor Positive Control for the LUMI-
59		CELL [®] ER Agonist Assay
60	RPMI	RPMI 1640 growth medium
61	T150	150 cm ² tissue culture flask

62 1.0 PURPOSE

63 This protocol is designed to evaluate substances for potential estrogen receptor (ER) agonist
64 activity using the LUMI-CELL[®] ER assay.

65 2.0 DEFINITIONS

- 66 • **Dosing Solution:** The test substance, control substance, or reference standard
67 solution, which is to be placed into the tissue culture wells for experimentation.
- 68 • **Raw Data:** Raw data includes information that has been collected but not
69 formatted or analyzed, and consists of the following:
 - 70 ○ Data recorded in the Study Notebook
 - 71 ○ Computer printout of initial luminometer data
 - 72 ○ Other data collected as part of GLP compliance, e.g.:
 - 73 ▪ Equipment logs and calibration records
 - 74 ▪ Test substance and tissue culture media preparation logs
 - 75 ▪ Cryogenic freezer inventory logs
- 76 • **Soluble:** Test substance exists in a clear solution without visible cloudiness or
77 precipitate.
- 78 • **Study Notebook:** The study notebook contains recordings of all activities related
79 to the conduct of the LUMI-CELL[®] ER assay.
- 80 • **Test Substances:** Substances supplied to the testing laboratories that are coded
81 and distributed such that only the Project Officer, Study Management Team
82 (SMT), and the Substance Inventory and Distribution Management have
83 knowledge of their true identity. The test substances will be purchased, aliquoted,
84 coded, and distributed by the Supplier under the guidance of the NIEHS/NTP
85 Project Officer and the SMT.

86 3.0 CONTROLS AND REFERENCE STANDARDS

87 Controls for the ER agonist protocol are as follows:

88 *Vehicle control (dimethyl sulfoxide [DMSO]):* 1% (v/v) DMSO (CASRN 67-68-5) diluted in
89 tissue culture media.

90 *Reference standard (17β-estradiol [E2]):* Three concentrations of E2 (CASRN 50-28-2) in
91 duplicate for range finder testing and a serial dilution consisting of 10 concentrations of E2 in
92 duplicate for comprehensive testing

93 *Positive control (p,p'-Methoxychlor [methoxychlor]):* Methoxychlor (CASRN 72-43-5), 3.13
94 µg/mL in tissue culture media, used as a weak positive control.

95 **4.0 OVERVIEW OF GENERAL PROCEDURES FOR AGONIST TESTING**

96 All experimental procedures are to be carried out under aseptic conditions and all solutions,
97 glassware, plastic ware, pipettes, etc., shall be sterile. All methods and procedures shall be
98 documented in the study notebook.

99 Agonist range finder testing is conducted on 96-well plates using four concentrations of E2 (5.00
100 $\times 10^{-5}$, 1.25×10^{-5} , 3.13×10^{-6} and 7.83×10^{-7} µg/mL) in duplicate as the reference standard and
101 four replicate wells for the DMSO control. Range finder testing uses all wells of the 96-well
102 plate to test six substances as seven point logarithmic serial dilutions in duplicate.

103 Comprehensive testing is conducted on 96-well plates using 11 concentrations of E2 in duplicate
104 as the reference standard (**Table 4-1**). Four replicate wells for the DMSO control and four
105 replicate wells for the methoxychlor control are included on each plate.

106 **Table 4-1 Concentrations of E2 Reference Standard Used in**
 107 **Comprehensive Testing**

E2 Concentrations ¹		
1.00 x 10 ⁻⁴	6.25 x 10 ⁻⁶	3.92 x 10 ⁻⁷
5.00 x 10 ⁻⁵	3.13 x 10 ⁻⁶	1.95 x 10 ⁻⁷
2.50 x 10 ⁻⁵	1.56 x 10 ⁻⁶	9.78 x 10 ⁻⁸
1.25 x 10 ⁻⁵	7.83 x 10 ⁻⁷	

108 ¹Concentrations are presented in µg/mL.

109 Visual observations for cell viability are conducted for all experimental plates just prior to
 110 LUMI-CELL® ER assay evaluation.

111 Luminescence data, measured in relative light units (RLUs), is corrected for background
 112 luminescence by subtracting the mean RLU value of the vehicle control (DMSO) wells from the
 113 RLU measurements for each of the other wells of the 96-well plate. Data is then graphed, and
 114 evaluated as follows:

- 115 • A response is considered positive for agonist activity when the average adjusted
 116 RLU for a given concentration is greater than the mean RLU value plus three
 117 times the standard deviation for the vehicle control.
- 118 • Any response below this threshold is considered negative for agonist activity.

119 Where possible, the concentration that causes a half-maximal response (EC₅₀) is calculated using
 120 a Hill function analysis for substances that are positive. The Hill function is a four-parameter
 121 logistic mathematical model relating the substance concentration to the response (typically
 122 following a sigmoidal curve) using the equation below:

$$123 \quad Y = \text{Bottom} + \frac{\text{Top} - \text{Bottom}}{1 + 10^{(\log EC_{50} - X)\text{HillSlope}}}$$

124 where Y = response (i.e., relative light units); X = the logarithm of concentration; Bottom = the
 125 minimum response; Top = the maximum response; log EC₅₀ = the logarithm of X as the response
 126 midway between Top and Bottom; and HillSlope describes the steepness of the curve. The model
 127 calculates the best fit for the Top, Bottom, HillSlope, and EC₅₀ parameters.

128 Acceptance or rejection of a test is based on evaluation of reference standard and control results
129 from each experiment conducted on a 96-well plate. Results for these controls are compared to
130 historical results compiled in the historical database.

131 **4.1 Range Finder Testing**

132 Agonist range finding for coded substances consists of a seven point, logarithmic serial dilution
133 using duplicate wells per concentration. Concentrations for comprehensive testing are selected
134 based on the response observed in range finder testing. If necessary, a second range finder test
135 can be conducted to clarify the optimal concentration range to test.

136 **4.2 Comprehensive Testing**

137 Comprehensive agonist testing for coded substances consists of 11 point, double serial dilutions,
138 with each concentration tested in triplicate wells of the 96-well plate.

139 **5.0 MATERIALS FOR LUMI-CELL[®] ER ASSAY AGONIST TESTING**


140 This section provides the materials needed to conduct LUMI-CELL[®] ER testing, with associated
141 brand names/vendors¹ in brackets.

142 **5.1 BG1Luc4E2 Cells:**

143 Human ovarian cancer cell line stably transfected with a plasmid containing an estrogen response
144 element pGudLuc7.0 (**Figure 5-1**) [XDS].

145

¹Brand names and vendors should not be considered an endorsement by the U.S. Government or any member of the U.S. Government; such information is provided as examples.

145 **Figure 5-1 pGudLuc7.ERE Plasmid.**

146

147 **5.2 Equipment and Supplies:**

148 General cell culture equipment, media and supplies suitable to a cell culture facility are needed.

149 Equipment, media, and supplies specific to the LUMI-CELL[®] ER assay are specified below.

150 Equivalent materials from other commercial sources can be used.

- 151 • Berthold Orion 1 Microplate Luminometer [Berthold Cat. No.: Orion 1 MPL3] or
- 152 equivalent and dedicated computer
- 153 • Shaker for 96-well plates
- 154 • BackSeal-96/384, white adhesive bottom seal for 96-well and 384-well microplate
- 155 [Perkin-Elmer, Cat. No. 6005199]
- 156 • 17 β -estradiol (CAS RN: 50-28-2)
- 157 • Culture tube 13 x 100mm (case) [Thomas Scientific Cat. No.: 10009186R38]
- 158 • DMSO, U.S.P. analytical grade
- 159 • Dulbecco's Modification of Eagle's Medium (DMEM), containing 4.5 g/L
- 160 glucose, with sodium pyruvate, without phenol red or L-glutamine
- 161 • Fetal Bovine Serum
- 162 • Fetal Bovine Serum, charcoal/dextran treated, triple 0.1 μ m sterile filtered
- 163 • Gentamycin Sulfate (G418), 50 mg/mL

- 164 • L-glutamine, 29.2 mg/mL
- 165 • Luciferase Assay System (10-Pack) [Promega Cat. No. E1501]
- 166 • Lysis Solution 5X [Promega, Cat. No. E1531]
- 167 • Methoxychlor (CAS RN: 72-43-5)
- 168 • Penicillin/streptomycin solution, 5000 I.U. penicillin, 5000 µg/mL streptomycin
- 169 • Phosphate buffered saline (PBS, 1X) without calcium and magnesium
- 170 • RPMI 1640 medium, containing L-glutamine
- 171 • Trypsin (10X), 2.5% in Hank's balanced salt solution (HBSS), without calcium
- 172 and magnesium, without phenol red

173 Equipment should be maintained and calibrated as per GLP guidelines and individual laboratory
174 SOPs.

175 **6.0 PREPARATION OF TISSUE CULTURE MEDIA AND SOLUTIONS**

176 **6.1 RPMI 1640 Growth Medium (RPMI)**

177 RPMI 1640 is supplemented with 0.9% Pen-Strep and 8.0% FBS to make RPMI growth medium
178 (RPMI).

- 179 1. Remove FBS from -70°C freezer, and Pen-Strep from -20°C freezer and allow to
180 equilibrate to room temperature.
- 181 2. Add 44 mL of FBS and 5 mL Pen-Strep to the bottle of RPMI 1640.

182 *Store at 2-8°C for no longer than six months or until the shortest expiration date of any media*
183 *component.*

184 **6.2 Estrogen-free DMEM Medium**

185 DMEM is supplemented to contain 4.5% charcoal/dextran treated FBS, 1.9% L-glutamine, 0.9%
186 Pen-Strep.

- 187 1. Remove charcoal/dextran treated FBS from -70°C freezer, and L-glutamine and
188 Pen-Strep from -20°C freezer and allow to equilibrate to room temperature.

- 189 2. Add 24 mL of charcoal/dextran treated FBS, 10 mL L-glutamine, and 5 mL Pen-
190 Strep to one 500 mL bottle of DMEM.

191 *Store at 2-8°C for no longer than six months or until the shortest expiration date of any media*
192 *component..*

193 **6.3 1X Trypsin Solution**

194 1X Trypsin solution is prepared by dilution from a 10X premixed stock solution. The 10X stock
195 solution should be stored in 10 mL aliquots in a -20°C freezer.

196 Procedure for making 100 mL of 1X trypsin:

- 197 1. Remove a 10 mL aliquot of 10X trypsin from -20°C freezer and allow to
198 equilibrate to room temperature.
- 199 2. Aliquot 1 mL Trypsin (10X) along with 9 mL of 1X PBS into ten 15 mL sterile
200 centrifuge tubes.

201 *1X Trypsin should be stored at -20°C.*

202 **6.4 1X Lysis Solution**

203 Lysis solution is prepared by dilution from a 5X premixed stock solution. Both the 5X and 1X
204 solutions can be repeatedly freeze-thawed.

205 The procedure for making 10 mL of 1X lysis solution:

- 206 1. Thaw the 5X Promega Lysis solution and allow it to reach room temperature.
- 207 2. Remove 2 mL of 5X solution and place it in a 15 mL conical centrifuge tube.
- 208 3. Add 8 mL of distilled, de-ionized water to the conical tube.
- 209 4. Cap and shake gently until solutions are mixed.

210 *Store at -20°C for no longer than 1 year from receipt.*

211

212

212 **6.5 Reconstituted Luciferase Reagent**

213 Luciferase reagent consists of two components, luciferase buffer and lyophilized luciferase
214 substrate.

215 *For long term storage, unopened containers of the luciferase buffer and lyophilized luciferase*
216 *substrate can be stored at -70°C for up to one year.*

217 To reconstitute luciferase reagent:

- 218 1. Remove luciferase buffer and luciferase substrate from -70°C freezer and allow
219 them to equilibrate to room temperature.
- 220 2. Add 10 mL of luciferase buffer solution to luciferase substrate container and swirl
221 or vortex gently to mix; the Luciferase substrate should readily go into solution.
- 222 3. After solutions are mixed, aliquot to a 15mL centrifuge tube.
- 223 4. Store complete solution at -20°C.

224 *Reconstituted luciferase reagent is stable for up to 1 month at -20°C.*

225 **7.0 OVERVIEW OF PROPAGATION AND EXPERIMENTAL PLATING OF** 226 **BG1Luc4E2 CELLS**

227 BG-1 cells are grown as a monolayer in tissue culture flasks in a dedicated tissue culture
228 incubator at 37°C ± 1°C, 90% ± 5% humidity, and 5.0% ± 1% CO₂/air. The cells should be
229 examined, on a daily basis during working days, under an inverted phase contrast microscope
230 and any changes in morphology and/or adhesive properties must be noted in the study notebook.

231 Two T150 flasks containing cells at 80 to 90% confluence will usually yield a sufficient number
232 of cells to fill four 96-well plates for use in experiments.

233 **7.1 Conditioning in Estrogen-free Medium, and Plating Cells for Experimentation**

234 Cells must be conditioned to an estrogen-free environment 48 to 72 hours prior to plating the
235 cells in 96-well plates for analysis of estrogen dependent induction of luciferase activity. Cells
236 conditioned in estrogen-free medium are then plated (in estrogen-free medium) into 96-well
237 plates at a plating density of 200,000 cells/mL.

238 **8.0 PREPARATION OF TEST SUBSTANCES**

239 The solvent used for dissolution of test substances is 100% DMSO. All test substances should be
240 allowed to equilibrate to room temperature before being dissolved and diluted. Test substance
241 solutions (except for reference standards and controls) should not be prepared in bulk for use in
242 subsequent tests. Test substances are to be used within 24 hours of preparation. Solutions should
243 not have noticeable precipitate or cloudiness.

244 All information on weighing, solubility testing, and calculation of final concentrations for test
245 substances, reference standards and controls is to be recorded in the study notebook.

246 **8.1 Preparation of Reference Standards, Control and Test Substances for Range** 247 **Finder and Comprehensive Testing**

248 8.1.1 Preparation of Reference Standard and Control Stock Solutions

249 Stock solutions of E2 (1.0×10^{-2} µg/mL) and methoxychlor (313 µg/mL) are prepared in 100%
250 DMSO and stored at room temperature for up to three years or until the expiration date listed in
251 the certificate of analysis for that substance.

252 8.1.2 Preparation of Reference Standard, Control and Test Substance Dosing Solutions for 253 Range Finder Testing

254 Range finder testing is conducted on 96-well plates using four concentrations of E2 (5.00×10^{-5} ,
255 1.25×10^{-5} , 3.13×10^{-6} and 7.83×10^{-7} µg/mL) in duplicate as the reference standard. Four
256 replicate wells are used for the DMSO control. Test substances are to be tested at 7 logarithmic
257 dilutions starting at the highest soluble concentration of test substance.

258 8.1.3 Preparation of Reference Standard and Control Dosing Solutions for Comprehensive 259 Testing

260 Comprehensive testing is conducted on 96-well plates using 11 concentrations of E2 (1.0×10^{-4} ,
261 5.0×10^{-5} , 2.5×10^{-5} , 1.25×10^{-5} , 6.25×10^{-6} , 3.13×10^{-6} , 1.56×10^{-6} , 7.83×10^{-7} , 3.92×10^{-7} , 1.95
262 $\times 10^{-7}$, 9.78×10^{-8} µg/mL) in duplicate as the reference standard. Four replicate wells for the
263 DMSO and methoxychlor control are included on each plate.

264

265 8.1.4 Preparation of Test Substance Dosing Solutions for Comprehensive Testing

266 Comprehensive testing experiments are used to determine whether a substance possesses ER
 267 agonist activity in the LUMI-CELL® ER assay. Agonist comprehensive testing for coded
 268 substances consists of 11 point, double serial dilutions, with each concentration tested in
 269 triplicate wells of the 96-well plate.

270 Start the 11-point serial dilution series at a single log dilution higher than the concentration
 271 giving the highest adjusted RLU value during the range finder (e.g., if the highest adjusted RLU
 272 value occurred at a concentration of 0.01 mg/mL, start the serial dilution at 0.1 mg/mL).

273 **9.0 DATA ANALYSIS**

274 Prior to measurement of luminescence, remove treated plates from the incubator. Remove media,
 275 then perform visual inspection of cell viability using the scoring in **Table 9-1**.

276 **Table 9-1 Visual Observation Scoring**

Viability Score	Brief Description ¹
1	Normal Cell Morphology and Cell Density
2	Altered Cell Morphology and/or Small Gaps between Cells
3	Altered Cell Morphology and/or Large Gaps between Cells
4	Few (or no) Visible Cells
P	Wells containing precipitation are to be noted with "P"

277 ¹Reference photomicrographs are provided in the LUMI-CELL® ER Validation Study "Visual Observation Cell
 278 Viability Manual."
 279

280 Luminescence is measured in the range of 300 to 650 nm, using an injecting luminometer and
 281 with software that controls the injection volume and measurement interval. Light emission from
 282 each well is expressed as RLU per well.

283

284 **9.1 Adjusting and Normalizing RLU Values**

285 Subtract background luminescence (average DMSO solvent control RLU value) from test
 286 substance, reference standard and control RLU values. Plate induction is calculated using these
 287 corrected RLU values. Test substance, reference standard, and control RLU values are then
 288 adjusted relative to the highest E2 reference standard RLU value, which is set to 10,000.

289

289 9.1.1 Determination of Outliers

290 The Study Director will use good statistical judgment for determining “unusable” wells that will
291 be excluded from the data analysis and will provide an explanation in the study notebook for any
292 excluded data.

293 9.1.2 Acceptance Criteria

294 Acceptance or rejection of a test is based on evaluation of reference standard and control results
295 from each experiment conducted on a 96-well plate. Results are compared to quality controls
296 (QC) for these parameters derived from the historical database, which are summarized below.

- 297 • Induction: Plate induction, as measured by dividing the averaged highest E2
298 reference standard RLU value by the averaged DMSO control RLU value, must
299 be greater than three-fold.
- 300 • Reference standard results: Calculated E2 reference standard EC₅₀ values must be
301 within 2.5 times the standard deviation of the historical database EC₅₀ mean
302 value.
- 303 • Solvent control results: Solvent control RLU values must be within 2.5 times the
304 standard deviation of the historical solvent control mean RLU value.
- 305 • Positive control results: Methoxychlor control RLU values must be within 2.5
306 times the standard deviation of the historical methoxychlor control mean RLU
307 value.

308 An experiment that fails any single acceptance criterion will be discarded and repeated.

309 **10.0 RANGE FINDER TESTING**

310 To determine starting concentrations for comprehensive testing use the following criteria:

- 311 • If there are no points on the test substance concentration curve that are above the
312 line representing the mean plus three times the standard deviation of the DMSO
313 control, the highest concentration used in comprehensive testing is the limit dose
314 or the maximum soluble dose.
- 315 • If there are points on the test substance concentration curve that are above the line
316 representing the mean plus three times the standard deviation of the DMSO

317 control, select a concentration that is a single log dilution higher than the
318 concentration giving the highest adjusted RLU value in the range finder, and use
319 that as the highest concentration for comprehensive testing.

320 • If a substance exhibits a biphasic concentration curve, the range finder experiment
321 should be repeated unless the proposed concentration range for the comprehensive
322 studies will include all concentrations of the biphasic region in the range finding
323 study. If the range finder experiment is repeated and the substance still exhibits a
324 biphasic concentration curve, comprehensive testing must be conducted on the
325 peak of the biphasic curve at the lowest test substance concentration. If the
326 substance is negative at this lowest concentration, then test at the higher
327 concentration. For either peak of the concentration curve, select a concentration
328 that is a single log dilution higher than the concentration giving the highest
329 adjusted RLU value in the range finder and use that as the highest concentration
330 for comprehensive testing.

331 **11.0 COMPREHENSIVE TESTING**

332 Evaluate whether comprehensive experiments have met acceptance criteria (see **Section 9.1.2**).

- 333 • If the substance has been tested up to the limit dose or the maximum soluble dose,
334 without causing a significant decrease in cell viability, and there are no points on
335 the concentration curve that are above the line indicating the mean plus three
336 times the standard deviation of the DMSO control, the substance is considered
337 negative for agonism
- 338 • If the substance has a positive response at any concentration, the substance is
339 considered positive for agonism.

340